The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Urogenital Neoplasms

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Urogenital Neoplasms


High impact information on Urogenital Neoplasms


Chemical compound and disease context of Urogenital Neoplasms


Biological context of Urogenital Neoplasms


Anatomical context of Urogenital Neoplasms


Gene context of Urogenital Neoplasms


Analytical, diagnostic and therapeutic context of Urogenital Neoplasms


  1. Effect of recombinant human granulocyte colony-stimulating factor in patients receiving chemotherapy for urogenital cancer. Urological rhG-CSF Study Group. Aso, Y., Akaza, H. J. Urol. (1992) [Pubmed]
  2. Evaluation of prostate-specific antigen as a marker for adenocarcinoma of the prostate. Barak, M., Mecz, Y., Lurie, A., Gruener, N. J. Lab. Clin. Med. (1989) [Pubmed]
  3. Auditory toxicity effects of long-term cis-dichlorodiammineplatinum II therapy in genitourinary cancer patients. Aguilar-Markulis, N.V., Beckley, S., Priore, R., Mettlin, C. Journal of surgical oncology. (1981) [Pubmed]
  4. The effects of treatment on delayed cutaneous hypersensitivity responses (DNCB, croton oil, and recall antigen) in patients with genitourinary cancer. Elhilali, M.M., Brosman, S.A., Vescera, C., Paul, J.G., Fahey, J.L. Cancer (1978) [Pubmed]
  5. Current management of unusual genitourinary cancers. Part 1: Penile cancer. Krieg, R., Hoffman, R. Oncology (Williston Park, N.Y.) (1999) [Pubmed]
  6. Intracellular Na+:K+ ratios in human cancer cells as revealed by energy dispersive x-ray microanalysis. Nagy, I.Z., Lustyik, G., Nagy, V.Z., Zarándi, B., Bertoni-Freddari, C. J. Cell Biol. (1981) [Pubmed]
  7. Epigenetic regulation of coxsackie and adenovirus receptor (CAR) gene promoter in urogenital cancer cells. Pong, R.C., Lai, Y.J., Chen, H., Okegawa, T., Frenkel, E., Sagalowsky, A., Hsieh, J.T. Cancer Res. (2003) [Pubmed]
  8. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. de Wit, R., Roberts, J.T., Wilkinson, P.M., de Mulder, P.H., Mead, G.M., Fosså, S.D., Cook, P., de Prijck, L., Stenning, S., Collette, L. J. Clin. Oncol. (2001) [Pubmed]
  9. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. de Wit, R., Stoter, G., Kaye, S.B., Sleijfer, D.T., Jones, W.G., ten Bokkel Huinink, W.W., Rea, L.A., Collette, L., Sylvester, R. J. Clin. Oncol. (1997) [Pubmed]
  10. Axillary lymphoscintigraphy by radioimmunodetection of carcinoembryonic antigen in breast cancer. Kim, E.E., Corgan, R.L., Casper, S., Primus, F.J., Spremulli, E., Estes, N., Goldenberg, D.M. J. Nucl. Med. (1979) [Pubmed]
  11. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. Bouffioux, C., Kurth, K.H., Bono, A., Oosterlinck, W., Kruger, C.B., De Pauw, M., Sylvester, R. J. Urol. (1995) [Pubmed]
  12. Future directions for gemcitabine in the treatment of genitourinary cancer. Vogelzang, N.J. Semin. Oncol. (2002) [Pubmed]
  13. Skin testing in genitourinary carcinoma: 2-year followup. Decenzo, J.M., Allison, R., Leadbetter, G.W. J. Urol. (1975) [Pubmed]
  14. Brief communication: use of the multitargeted antifolate pemetrexed (Alimta) in genitourinary cancer. Misset, J.L. Semin. Oncol. (2002) [Pubmed]
  15. Phase II study of cis-diammine(glycolato)platinum, 254-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract. 254-S Urological Cancer Study Group. Akaza, H., Togashi, M., Nishio, Y., Miki, T., Kotake, T., Matsumura, Y., Yoshida, O., Aso, Y. Cancer Chemother. Pharmacol. (1992) [Pubmed]
  16. Human papillomavirus E6 and E7 oncoproteins alter cell cycle progression but not radiosensitivity of carcinoma cells treated with low-dose-rate radiation. DeWeese, T.L., Walsh, J.C., Dillehay, L.E., Kessis, T.D., Hedrick, L., Cho, K.R., Nelson, W.G. Int. J. Radiat. Oncol. Biol. Phys. (1997) [Pubmed]
  17. Synergistic effects of Cox-1 and -2 inhibition on bladder and prostate cancer in vitro. Farivar-Mohseni, H., Kandzari, S.J., Zaslau, S., Riggs, D.R., Jackson, B.J., McFadden, D.W. Am. J. Surg. (2004) [Pubmed]
  18. Indomethacin modulation of monocyte cytokine release following pelvic irradiation for cancer. Petrini, B., Wolk, G., Wasserman, J., Vedin, I., Strannegård, O., Blomgren, H., Esposti, P.L. Eur. J. Cancer (1991) [Pubmed]
  19. Evaluation of cellular fluidity of peripheral blood lymphocytes from patients with urogenital cancers by a fluorescence polarization technique: PHA response and prognosis. Sakamoto, S., Maeda, H., Yamasaki, K., Aikawa, S., Hinuma, Y. European journal of cancer & clinical oncology. (1981) [Pubmed]
  20. COX-2 inhibitors and other nonsteroidal anti-inflammatory drugs in genitourinary cancer. Sabichi, A.L., Lippman, S.M. Semin. Oncol. (2004) [Pubmed]
  21. The clinical utility of plasma and urinary carcinoembryonic antigen in patients with genitourinary disease. Fleisher, M., Grabstald, H., Whitmore, W.F., Pinsky, C.M., Oettgen, H.F., Schwartz, M.K. J. Urol. (1977) [Pubmed]
  22. Glycopeptides (FSH, LH, TSH, prolactin) and glycoproteins in patients with genitourinary cancer. Dunzendorfer, U., Schumann, W., Drahovsky, D., Ohlenschläger, G. Oncology (1981) [Pubmed]
  23. Antibodies to cytokeratin filaments in patients with alcoholic liver disease. Kurki, P., Virtanen, I., Lehto, V.P., Alfthan, O., Salaspuro, M. Alcohol. Clin. Exp. Res. (1984) [Pubmed]
  24. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies. Nelson, W.G., Simons, J.W., Mikhak, B., Chang, J.F., DeMarzo, A.M., Carducci, M.A., Kim, M., Weber, C.E., Baccala, A.A., Goeman, M.A., Clift, S.M., Ando, D.G., Levitsky, H.I., Cohen, L.K., Sanda, M.G., Mulligan, R.C., Partin, A.W., Carter, H.B., Piantadosi, S., Marshall, F.F. Cancer Chemother. Pharmacol. (2000) [Pubmed]
  25. Tissue polypeptide antigen (TPA) as a predictor for genitourinary cancers and their metastases. Khanna, O.P., Wu, B. Urology (1987) [Pubmed]
WikiGenes - Universities